Back to Search Start Over

Schisandrin B attenuates renal fibrosis via miR-30e-mediated inhibition of EMT.

Authors :
Cao G
Li S
Shi H
Yin P
Chen J
Li H
Zhong Y
Diao LT
Du B
Source :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2019 Dec 15; Vol. 385, pp. 114769. Date of Electronic Publication: 2019 Nov 05.
Publication Year :
2019

Abstract

Tubulointerstitial fibrosis (TIF) is the main pathologic feature of end-stage renal disease. Epithelial-mesenchymal transition (EMT) of proximal tubular cells (PTCs) is one of the most significant features of TIF. MicroRNAs play critical roles during EMT in TIF. However, whether miRNAs can be used as therapeutic targets in TIF therapy remains undetermined. We found that miR-30e, a member of the miR-30 family, is deregulated in TGF-β1-induced PTCs, TIF mice and human fibrotic kidney tissues. Moreover, transcription factors that induce EMT, such as snail, slug, and Zeb2, were direct targets of miR-30e. Using a cell-based miR-30e promoter luciferase reporter system, Schisandrin B (Sch B) was selected for the enhancement of miR-30e transcriptional activity. Our results indicate that Sch B can decrease the expression of snail, slug, and Zeb2, thereby attenuating the EMT of PTCs during TIF by upregulating miR-30e, both in vivo and in vitro. This study shows that miR-30e can serve as a therapeutic target in the treatment of patients with TIF and that Sch B may potentially be used in therapy against renal fibrosis.<br /> (Copyright © 2019 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1096-0333
Volume :
385
Database :
MEDLINE
Journal :
Toxicology and applied pharmacology
Publication Type :
Academic Journal
Accession number :
31697999
Full Text :
https://doi.org/10.1016/j.taap.2019.114769